XASX
NAN
Market cap582mUSD
Oct 09, Last price
2.84AUD
1D
1.43%
1Q
-12.35%
Jan 2017
-8.68%
IPO
268.83%
Name
Nanosonics Ltd
Chart & performance
P/E
47.60
P/S
4.17
EPS
0.06
Div yield, %
—
Shrs. gr., 5y
0.24%
Rev. gr., 5y
14.85%
Revenues
203m
+2.28%
Net income
18m
-13.74%
CFO
23m
-48.73%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Nanosonics Limited, along with its subsidiaries, functions as a global infection prevention enterprise with operations in Australia and beyond. The company focuses on the production and distribution of its trophon ultrasound probe disinfection system, including all related supplies and accessories. Additionally, it dedicates resources to the exploration, development, and market launch of innovative infection control, decontamination products, and their associated technologies. Key offerings from Nanosonics include trophon2, an advanced device for high-level disinfection of ultrasound probes; trophon EPR, a low-temperature, high-level disinfection method specifically for intra-cavity ultrasound probes; and Nanosonics AuditPro, a comprehensive solution for managing compliance with infection control workflows. Established in 2000, Nanosonics Limited is headquartered in Macquarie Park, Australia.
Key people
Non-Executive Chairman of the Board · since 2007
Michael Kavanagh
President, Chief Executive Officer, Managing Director, Executive Director · since 2013
McGregor Grant
Chief Financial Officer, Company Secretary · since 2011
Chief Strategy Officer and Regional President Asia Pacific · since 2019
Rod Lopez
Chief Operating Officer · since 2019
Steven Farrugia
Chief Technology Officer · since 2018
Renee Salaberry
Chief Marketing Officer · since 2019
Leanne Baxendale
Head of People and Culture · since 2017
Geoff Wilson
Non-Executive Director · since 2019
Independent Non-Executive Deputy Chairman of the Board · since 2016
David Fisher
Independent Non-Executive Director · since 2008
Marie Elizabeth McDonald
Non-Executive Independent Director · since 2016
Headquarters & legal address
Level 1, Building A, 7-11 Talavera Road
Macquarie Park
Sydney, NSW 2113
AU
Macquarie Park
Sydney, NSW 2113
AU
Previous name
NANOSONICS PTY LTD
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑06 | 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||